Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL735234 | 0.85 | IDO1 (0.59) | SMN1; SMN2TSHRHSD17B10IDO1TDO2 | |
| SCHEMBL12747117 | 0.84 | PDK2 (0.46) | SMN1; SMN2TSHRHSD17B10IDO1TDO2 | |
| SCHEMBL7610577 | 0.81 | SMN1; SMN2 (0.47) | SMN1; SMN2IDO1TDO2ALDH1A1LMNA | |
| SCHEMBL18552440 | 0.79 | ALDH1A1 (0.43) | SMN1; SMN2TSHRHSD17B10IDO1TDO2 | |
| SCHEMBL7609094 | 0.78 | SMN1; SMN2 (0.55) | SMN1; SMN2IDO1TDO2ALDH1A1LMNA | |
| SCHEMBL14609116 | 0.78 | BRD4 (0.40) | SMN1; SMN2TSHRIDO1ADCY8ALDH1A1 | |
| SCHEMBL29695374 | 0.76 | PDK2 (0.57) | SMN1; SMN2LMNAPDK2PDK4GAA | |
| SCHEMBL3520823 | 0.76 | PDK2 (0.57) | SMN1; SMN2LMNAPDK2PDK4GAA | |
| SCHEMBL24390030 | 0.75 | PPID (0.43) | SMN1; SMN2TSHRHSD17B10IDO1TDO2 | |
| SCHEMBL7610094 | 0.75 | SMN1; SMN2 (0.42) | SMN1; SMN2IDO1TDO2ADCY8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7749994-B2 | Pentacyclic kinase inhibitors | GENENTECH, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7749994-B2 | Pentacyclic kinase inhibitors | GENENTECH, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| WO-2007022102-A2 | PENTACYCLIC KINASE INHIBITORS | GENENTECH, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037791-A1 | serine/threonine kinase inhibitors, useful for therapy and/or prophylaxis of cancers in mammals | HOFFMAN-LAROUCHE, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037791-A1 | serine/threonine kinase inhibitors, useful for therapy and/or prophylaxis of cancers in mammals | HOFFMAN-LAROUCHE, INC. | 2007-02-15 | — | — | US | disclosed |
| EP-0685463-B1 | INDOLIN-2-ONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2002-05-22 | — | — | EP | disclosed |
| US-6207836-B1 | Indolin-2-one derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-03-27 | — | — | US | disclosed |
| US-6127544-A | 1-SUBSTITUTED-3-UREIDO-INDOLIN-2-ONES WHICH EXHIBIT SELECTIVE ANTAGONISM AGAINST GASTRIN RECEPTORS WITHOUT CAUSING SIDE EFFECTS ATTRIBUTED TO CCK-A RECEPTOR ANTAGONISM; SUCH AS FOR TREATMENT OF PEPTIC ULCERS, GASTRITIS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-10-03 | — | — | US | disclosed |
| US-6114536-A | ANTAGONISM AGAINST GASTRIN RECEPTORS WITHOUT CAUSING SIDE EFFECTS ATTRIBUTED TO CCK-A RECEPTOR ANTAGONISM AND ARE USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES OF DIGESTIVE ORGANS, SUCH AS PEPTIC ULCER, GASTRITIS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-09-05 | — | — | US | disclosed |
| US-6031111-A | Indolin-2-one derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-02-29 | — | — | US | disclosed |
| US-5952511-A | EXHIBITS SELECTIVE ANTAGONISM AGAINST GASTRIN RECEPTOR WITHOUT CAUSING SIDE EFFECTS ATTRIBUTED TO GASTRIN RECEPTOR ANTAGONISM AND USEFUL FOR TREATING PEPTIC ULCER, GASTRITIS, REFLUX ESOPHAGITIS AND ZOLLINGER-ELLISON SYNDROME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1999-09-14 | — | — | US | disclosed |
| EP-0685463-A1 | INDOLIN-2-ONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 1995-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037791-A1 | serine/threonine kinase inhibitors, useful for therapy and/or prophylaxis of cancers in mammals | RAF1, CHEK1, BRAF | SMN1; SMN2 3254/4885TSHR 793/4885HSD17B10 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.